Korio, a Doylestown, PA-based randomization and trial supply management (RTSM) technology company, raised an undisclosed amount in Series A Funding.
The round was led by BIP Ventures, with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners, and other strategic investors.
The company intends to use the funds to accelerate its continued global expansion, with focus on its expert client services and support team.
Led by CEO Ryan Keane, Korio provides a randomization and trial supply management (RTSM) platform for clinical trial quality, speed and reliability. It enables users to adapt to protocol changes, surface audit trail and cross-portfolio data, flag integration disruptions – and when they need guidance, provide access to knowledgeable and responsive RTSM experts.
FinSMEs
10/09/2024